Bavencio 20 mg/mL concentrate for solution for infusion, Inlyta 5 mg film-coated tablets clinical trials

Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence (N17JAV)

This study is looking at a new combination of two drugs, axitinib and avelumab, for people with a common type of kidney cancer before surgery. The main goal is to see how well this drug combination shrinks the cancer.